Literature DB >> 33515347

Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer.

Zeynep Ozman1, Betul Ozbek Iptec2, Elvan Sahin3, Gamze Guney Eskiler4, Asuman Deveci Ozkan5, Suleyman Kaleli4.   

Abstract

Valproic acid (VPA) is a selective histone deacetylation (HDAC) inhibitor and exerts anti-cancer properties in different types of cancer. The epithelial-to-mesenchymal transition (EMT) mediating by different signaling cascade can be a potential target in aggressive human cancers. Therefore, we aimed to clarified the unravel relationship between AKT/GSK3β/β-catenin signalling pathway and VPA-induced EMT in triple negative breast cancer (TNBC). The cytotoxicity of VPA in MDA-MB-231 TNBC and MCF-10A control cells was evaluated. Alterations in the expression levels of Snail, E-cadherin, AKT, GSK3β, β-catenin were analyzed by RT-PCR. Additionally, Annexin V, cell cycle and wound healing assays were performed. Our results showed that VPA remarkably inhibited the growth of TNBC cell and triggered apoptotic cell death through G0/G1 arrest. Furthermore, VPA increased cell migration and activated the EMT process through significantly increasing Snail expression and in turn downregulation of E-cadherin and GKS3β levels. However, the level of AKT and β-catenin was reduced after treatment of VPA. Our data showed that VPA induced EMT process and cell migration in TNBC cells. However, AKT/GSK3β/β-catenin signaling pathway did not mediate EMT activation.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition; GSK3β; Triple negative breast cancer; Valproic acid

Mesh:

Substances:

Year:  2021        PMID: 33515347     DOI: 10.1007/s11033-021-06173-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  4 in total

Review 1.  [Histone modification and its application in therapy for hematologic malignancies -- review].

Authors:  Ming-Hao Fang; Xue-Mei Ji
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2009-06

2.  Re-Evaluating E-Cadherin and β-Catenin: A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer.

Authors:  Nicholas Borcherding; Kimberly Cole; Paige Kluz; Michael Jorgensen; Ryan Kolb; Andrew Bellizzi; Weizhou Zhang
Journal:  Am J Pathol       Date:  2018-06-04       Impact factor: 4.307

3.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

4.  Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer.

Authors:  Tiansheng Shen; Kui Zhang; Gene P Siegal; Shi Wei
Journal:  Am J Clin Pathol       Date:  2016-11-01       Impact factor: 2.493

  4 in total
  2 in total

Review 1.  Differential molecular mechanistic behavior of HDACs in cancer progression.

Authors:  Tashvinder Singh; Prabhsimran Kaur; Paramdeep Singh; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 2.  Regulation of epithelial-mesenchymal transition by protein lysine acetylation.

Authors:  Fanyun Kong; Lihong Ma; Xing Wang; Hongjuan You; Kuiyang Zheng; Renxian Tang
Journal:  Cell Commun Signal       Date:  2022-04-28       Impact factor: 7.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.